12/24
07:46 am
galt
Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains [Seeking Alpha]
Low
Report
Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains [Seeking Alpha]
12/19
10:04 am
galt
Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line [Yahoo! Finance]
Medium
Report
Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line [Yahoo! Finance]
12/19
08:10 am
galt
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 [Yahoo! Finance]
High
Report
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 [Yahoo! Finance]
12/19
08:00 am
galt
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
High
Report
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
12/17
07:19 am
galt
Galectin Therapeutics (NASDAQ:GALT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Galectin Therapeutics (NASDAQ:GALT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/4
08:45 am
galt
Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data [Seeking Alpha]
Medium
Report
Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data [Seeking Alpha]
11/14
08:22 am
galt
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update [Yahoo! Finance]
Medium
Report
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update [Yahoo! Finance]
11/14
08:13 am
galt
Galectin Therapeutics GAAP EPS of -$0.13 [Seeking Alpha]
Low
Report
Galectin Therapeutics GAAP EPS of -$0.13 [Seeking Alpha]
11/14
08:00 am
galt
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
Medium
Report
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
11/10
08:00 am
galt
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
Medium
Report
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
10/20
08:00 am
galt
Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
Low
Report
Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
10/7
08:27 am
galt
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 [Yahoo! Finance]
Medium
Report
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 [Yahoo! Finance]
10/7
08:00 am
galt
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025
Low
Report
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025